Comparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis

This randomized controlled trial aims to compare the efficacy and safety of oral methotrexate and tofacitinib in patients with chronic plaque psoriasis. Participants diagnosed with chronic plaque psoriasis will be randomly assigned to receive either methotrexate or tofacitinib and will be followed for six months. Clinical improvement, disease severity, treatment response, and adverse effects will be assessed and compared between the two treatment groups.

NCT Number	NCT07581418
Lead Sponsor	Pak Emirates Military Hospital
Conditions	Chronic Plaque Psoriasis
Enrollment	88 participants
Start Date	2026-06-01
Primary Completion	2026-12-01 (estimated)
Study Completion	2026-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-12